Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: catabasis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2021 | $16.00 | Outperform | Wedbush |
| 8/25/2021 | $13.00 | Neutral → Buy | HC Wainwright & Co. |
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with hereditary angioedema to prevent attacks," said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. "We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated
SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13D/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13D/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13D - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13G - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13G - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13G/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
SC 13G/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
-- Astria Reflects Company's Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company's commitment to having patients serve as guiding stars. Astria's mission is to bring hope with life-changing therapies to patients and famili
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with hereditary angioedema to prevent attacks," said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. "We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET. The session entitled "HAE There- Development Landscape in Hereditary Angioedema (HAE)" will include an overview of the HAE treatment landscape, information about Catabasis's lead program QLS-215, and a Q&A session. A webcast of the presentation will be available at the following link: https://wsw.com/webcast/wedbush39/panel11/2571740, and will also be available in the investors section of the Company's
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET. A webcast of the presentation will be available at the following link: https://wsw.com/webcast/ladenburg7/catb/2378558, and will also be available in the investors section of the Company's website, www.catabasis.com, and will be archived for 30
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences: Oppenheimer Rare and Orphan Disease Summit. Presentations will be available on-demand on May 21, 2021. Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET. Webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will be available for 30 days following the even
-- QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein, Progresses in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Strong Cash Position of $146.9M Planned to Fund IND-Enabling Studies, Phase 1a and Phase 1b/2 Clinical Trials of QLS-215 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. "We see Catabasis as being in a strong position for 2021 thanks to the acquisition of Quellis and the concurrent financing earlier this year. Our team has completed the integration of the Quellis programs and
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. “With our acquisition of Quellis and concurrent financing, we believe Catabasis is well positioned to advance the development of our lead program, QLS-215, as a differentiated and potential best-in-class new therapy for the chronic treatment of patients affected by hereditary angioedema to prevent attacks,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “QLS-215 is a monoclonal antibody inhibitor of plasma kallikrein in preclinical developm
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month: H.C. Wainwright Global Life Sciences Conference. Presentations will be available on-demand from March 9-10, 2021. Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 10:00am ET. Webcasts of the events can be accessed from the investors section of www.catabasis.com. Ar
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. Concurrent with the acquisition of Quellis, Catabasis entered into a definitive agreement for the sale of Series X convertible preferred stock (the “Series X preferred stock”) in a private placement to a group of institutional accredited investors led by Perceptive Advisors, with participation from Fairmount Funds Management LLC, RA Capital Management, Cormorant Asset Managemen
Wedbush initiated coverage of Catabasis Pharmaceuticals with a rating of Outperform and set a new price target of $16.00
HC Wainwright & Co. upgraded Catabasis Pharmaceuticals from Neutral to Buy and set a new price target of $13.00
Ladenburg Thalmann initiated coverage of Catabasis Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Oppenheimer upgraded Catabasis Pharmaceuticals from Market Perform to Outperform
Oppenheimer upgraded Catabasis Pharmaceuticals from Perform to Outperform and set a new price target of $5.00
Oppenheimer downgraded Catabasis Pharmaceuticals from Outperform to Perform and set a new price target of $5.00
HC Wainwright resumed coverage of Catabasis Pharmaceuticals with a rating of Hold
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
S-8 - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
10-Q - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
8-K - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
424B5 - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
8-K/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
8-K - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
10-Q - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
10-K/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)